meta_pixel
Tapesearch Logo
Log in
The Clay Travis and Buck Sexton Show

Wellness Unmasked Weekly Rundown: FDA Cracks Down on Kratom Derivatives + Controversy Over AI in Healthcare

The Clay Travis and Buck Sexton Show

iHeartPodcasts

Politics, News, Society & Culture, News Commentary, Daily News

4.511.4K Ratings

🗓️ 1 August 2025

⏱️ 4 minutes

🧾️ Download transcript

Summary

In this Wellness Unmasked Weekly Rundown, Dr. Nicole Saphier breaks down two urgent developments in the world of health and wellness. First, she unpacks the FDA's move to schedule 7-hydroxymitragynine (7-OH)—a synthetic Kratom derivative up to 13 times stronger than morphine—as a Schedule I controlled substance. Then, Dr. Saphier dives into the White House’s new AI-driven healthcare initiative.

Transcript

Click on a timestamp to play from that location

0:00.0

Welcome to Wellness on Mass. I'm Dr. Nicole Sapphire, and this is your Wellness on Mass Weekly Rundown.

0:06.5

Let's start with the FDA's urgent move this week to restrict 7 Hydroxy Mitrogynine, also known as 70H, much easier to say.

0:14.7

It's a powerful synthetic derivative of kratom, often marketed in innocent-looking gummies, shots, and drink powders. But do not let that

0:22.7

colorful packaging fool you. 70H can be up to 13 times more potent than morphine. It's not your

0:29.3

grandma's herbal tea. It's more like legal morphine for sale at the gas station. So the FDA has officially

0:35.3

recommended scheduling 7-0-H as a Schedule 1 controlled substance, meaning it has no approved medical use, essentially like heroin, because it has such a high potential for abuse.

0:46.3

Now, this doesn't affect natural kratom leaf products, although I can tell you that I think that these are a little bit risky as well, but it's a line in the sand for these

0:55.6

lab enhanced versions being marketed as wellness supplements. Now, here's why this matters.

1:00.9

These products are completely unregulated, aggressively marketed to young people and sold

1:05.7

online and in stores with zero oversight. And let's be honest, many people consuming them have no idea what

1:12.7

they're actually taking. I applaud the FDA for stepping in, but the fact that these products

1:17.5

were allowed to flood the market in the first place shows us just how broken our whole regulatory

1:22.6

framework still is when it comes to these synthetic health trends. Now I want to pivot from fake drugs to real

1:30.3

tech. This week, the White House announced a bold new initiative. On the surface, it sounds exciting.

1:37.3

AI and healthcare, interoperability, data transparency, and streamlining medical coding and reimbursement,

1:46.1

and all of that. They have all of the tech companies, Amazon, Google, Apple, and all these others who are voluntarily stepping

1:50.4

up to be a part of this initiative. But if you've been on long enough, you know this isn't the

1:55.9

first time Washington has promised tech is going to fix health care. Remember the whole Affordable Care

2:01.5

Act's push for electronic medical records? Well, that mandate led to bloated software,

2:07.2

clunky workflows, and data breaches we're still recovering from. Not to mention, it forced

2:12.0

out a lot of physicians from private practice and a lot of people just left medicine altogether.

2:17.9

So yes, innovation is good, but let's not forget the side effects of it.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from iHeartPodcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of iHeartPodcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.